Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Glypican 3-specific Chimeric Antigen Receptor Expressing T Cells As Immunotherapy for Patients with Hepatocellular Carcinoma

NCT02905188 is registered in ClinicalTrials.gov with Baylor College of Medicine as lead sponsor.

NCT NCT02905188
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02905188 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Glypican 3-specific Chimeric Antigen Receptor Expressing T Cells As Immunotherapy for Patients with Hepatocellular Carcinoma
Lead sponsor
Baylor College of Medicine
Phase
Phase 1
Overall status
Completed
Start date
March 28, 2019
Completion date
January 6, 2023
Enrollment
9 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hepatocellular carcinoma